Advances in RNA sequencing have opened new frontiers in understanding how individual cells behave in healthy and diseased tissues. This is especially important for studying the human gastrointestinal (GI) tract, where diseases like colorectal cancer and inflammatory bowel disease often originate in epithelial cells—the cells lining the gut. These cells are critical for maintaining the barrier between our bodies and the external environment, but they are also incredibly delicate. Once removed from the tissue, they become highly vulnerable to stress, making them tricky to analyze with high-resolution techniques like single-cell RNA sequencing (scRNA-seq).

In a new study led by researchers at Harvard Medical School tackled this challenge head-on. They compared two widely used technologies for scRNA-seq: droplet-based (D-scRNA) and picowell-based (P-scRNA) platforms. Each has its strengths and weaknesses. Droplet-based systems are powerful and commonly used in research, but they involve enzymatic and mechanical processes that can stress fragile epithelial cells and introduce technical noise. They also require more equipment and resources. Picowell-based systems, on the other hand, capture cells in tiny wells using gentler processes, which may preserve more natural gene expression profiles and reduce sample degradation—but they’ve been less tested on actual human biopsy samples.

scRNA platform head-to-head comparison using the same single-cell pools

(A) Overview of (Ex)periments: (Ex1) effect of P-scRNA specific storage conditions; (Ex2) P-scRNA vs D-scRNA in Participant 1 and (Ex3) Participant 2, with tightly-controlled compartment loading. Blue cells indicate EPCAM+/CD45− epithelial cells, whereas orange indicates CD45+ non-epithelial cells. Unintegrated (B) and integrated (C) (accounting for platform and storage conditions) UMAP projections of Ex2, and (D) Ex3 projections with assigned cell types according to compartment fraction. Differences in rates of cells captured (E), genes detected (F), and mtDNA fraction(G) according to cell types and scRNA platform in Ex3.

This study is the first direct comparison of these two methods using human colon biopsies, which are a key sample type in translational GI research. The results revealed that picowell-based scRNA-seq can be a more cell-friendly, resource-efficient approach for profiling epithelial cells, especially when working with precious or limited tissue samples. While droplet methods still offer certain advantages in throughput and flexibility, the choice between the two should be guided by the specific needs of the study—particularly the sensitivity of the target cell type.

By carefully examining how these technologies perform in real clinical samples, the researchers provide a roadmap for others in the field. Their work not only highlights the importance of method selection in single-cell studies but also points the way toward better understanding of gut diseases through improved RNA sequencing techniques.